Media stories about Cancer Genetics (NASDAQ:CGIX) have been trending somewhat positive on Saturday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cancer Genetics earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 47.7765156772579 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
CGIX traded up $0.01 on Friday, reaching $0.98. The company’s stock had a trading volume of 88,156 shares, compared to its average volume of 122,650. The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $27.05 million, a price-to-earnings ratio of -1.24 and a beta of 1.04. Cancer Genetics has a fifty-two week low of $0.82 and a fifty-two week high of $3.50.
Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings results on Tuesday, August 14th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $8.80 million. Cancer Genetics had a negative return on equity of 81.99% and a negative net margin of 54.98%. equities analysts anticipate that Cancer Genetics will post -0.58 EPS for the current fiscal year.
CGIX has been the subject of a number of research analyst reports. Zacks Investment Research raised Cancer Genetics from a “sell” rating to a “hold” rating in a report on Monday, May 14th. HC Wainwright set a $3.00 price target on Cancer Genetics and gave the company a “buy” rating in a report on Tuesday, May 29th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Cancer Genetics in a report on Tuesday, August 14th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Cancer Genetics presently has a consensus rating of “Hold” and a consensus price target of $4.50.
About Cancer Genetics
Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Featured Article: Index Funds
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.